精神分裂症个体中哪些基因存在差异表达?一项系统综述
该系统综述检索PubMed、EmBase和Web of Science,纳入2000年1月1日至2020年6月30日发表的英文病例对照全基因组转录组研究,比较精神分裂症患者与健康对照的基因表达。分析发现差异表达基因与此前全基因组关联、外显子组测序和结构变异研究报告的基因不同,仅GBP2在五项研究中被重复。综述强调方法学不一致阻碍了有效Meta分析与合并。
要点
- 全转录组分析识别的差异表达基因与此前全基因组关联、外显子组测序和结构变异研究报告的基因不同。
- 仅GBP2一个基因在五项研究中被重复,此前研究提示该基因可能参与精神分裂症病因中的免疫功能。
- 综述强调协变量使用、基因命名和结果报告方法的不一致阻碍了有效的Meta分析与合并。
核心结论
- 全转录组分析识别的差异表达基因与此前全基因组关联、外显子组测序和结构变异研究报告的基因不同。
- 仅GBP2一个基因在五项研究中被重复,此前研究提示该基因可能参与精神分裂症病因中的免疫功能,进而可能对风险分析、预防和治疗有意义。
- 综述强调方法学不一致阻碍了有效的Meta分析与合并,协变量使用、基因命名和结果报告方法的标准化可增进对基因影响精神分裂症病因潜在机制的理解。
- 作者认为这些结果有前景,方法学协调的合作将促进识别精神分裂症潜在基因的作用。
研究设计与样本
- 研究为系统综述与合成,综合精神分裂症全基因组基因表达的病例对照研究。
- 在PubMed、EmBase和Web of Science完成全面文献检索。
- 纳入标准为2000年1月1日至2020年6月30日发表的英文人类病例对照研究,比较诊断为精神分裂症的个体与健康对照的全基因组转录组。
主要发现
- 从符合纳入标准的研究中提取病例的差异表达基因,并将重叠基因与此前全基因组关联、结构变异和组织表达研究的发现进行比较。
- 全转录组分析识别的差异表达基因与此前全基因组关联、外显子组测序和结构变异研究报告的基因不同。
- 仅GBP2一个基因在五项研究中被重复。
临床怎么用
- 原文未据此给出推荐。
局限性
- 综述强调方法学不一致阻碍了有效的Meta分析与合并。
- 协变量使用、基因命名和结果报告方法的不一致影响了研究间的比较与合成。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Schizophrenia is a severe, complex mental disorder characterized by a combination of positive symptoms, negative symptoms, and impaired cognitive function. Schizophrenia is highly heritable (~80%) with multifactorial etiology and complex polygenic genetic architecture. Despite the large number of genetic variants associated with schizophrenia, few causal variants have been established. Gaining insight into the mechanistic influences of these genetic variants may facilitate our ability to apply these findings to prevention and treatment. Though there have been more than 300 studies of gene expression in schizophrenia over the past 15 years, none of the studies have yielded consistent evidence for specific genes that contribute to schizophrenia risk. The aim of this work is to conduct a systematic review and synthesis of case-control studies of genome-wide gene expression in schizophrenia. Comprehensive literature searches were completed in PubMed, EmBase, and Web of Science, and after a systematic review of the studies, data were extracted from those that met the following inclusion criteria: human case-control studies comparing the genome-wide transcriptome of individuals diagnosed with schizophrenia to healthy controls published between January 1, 2000 and June 30, 2020 in the English language. Genes differentially expressed in cases were extracted from these studies, and overlapping genes were compared to previous research findings from the genome-wide association, structural variation, and tissue-expression studies. The transcriptome-wide analysis identified different genes than those previously reported in genome-wide association, exome sequencing, and structural variation studies of schizophrenia. Only one gene, GBP2, was replicated in five studies. Previous work has shown that this gene may play a role in immune function in the etiology of schizophrenia, which in turn could have implications for risk profiling, prevention, and treatment. This review highlights the methodological inconsistencies that impede valid meta-analyses and synthesis across studies. Standardization of the use of covariates, gene nomenclature, and methods for reporting results could enhance our understanding of the potential mechanisms through which genes exert their influence on the etiology of schizophrenia. Although these results are promising, collaborative efforts with harmonization of methodology will facilitate the identification of the role of genes underlying schizophrenia.
引用
- Merikangas AK, Shelly M, Knighton A, et al. What genes are differentially expressed in individuals with schizophrenia? A systematic review. Mol Psychiatry. 2022. PMID: 35091668. doi:10.1038/s41380-021-01420-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。